Beam Therapeutics Insider Sells $146K in Shares
Beam Therapeutics insider Christine Bellon sold 5,956 shares of the company's stock for over $146,000 to cover tax withholding obligations related to equity awards. Following the sale, she still owns over 109,711 shares valued at approximately $2.7 million. This transaction, executed under a pre-arranged trading plan, highlights the financial mechanics behind executive compensation rather than a negative outlook on the company.
Beam Therapeutics president sells $290k in shares
Giuseppe Ciaramella, President of Beam Therapeutics (NASDAQ:BEAM), sold 11,810 shares for approximately $290,289. This sale was automatically executed to cover tax withholding obligations related to restricted stock units. Despite the sale, the stock has seen a 59% return over the past year and analysts maintain "Outperform" ratings, citing promising clinical trial results for sickle cell disease and alpha-1 antitrypsin deficiency treatments.
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) President Sells $290,289.80 in Stock
Beam Therapeutics (NASDAQ:BEAM) President Giuseppe Ciaramella sold 11,810 shares of the company's stock for $290,289.80 on April 1st, reducing his stake by 5.13%. This sale was conducted under a pre-arranged Rule 10b5-1 plan to cover tax withholding obligations. The company recently exceeded earnings and revenue estimates and holds a "Moderate Buy" consensus rating from analysts.
Beam Therapeutics (BEAM) CMO covers tax obligations via 6,700-share sale
Beam Therapeutics' Chief Medical Officer, Amy Simon, reported selling 6,700 shares of common stock at $24.58 per share. This transaction was automatically executed under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations associated with the vesting of restricted stock units. Following the sale, Simon directly holds 102,735 Beam shares, which includes acquisitions through the company's Employee Stock Purchase Plan.
[Form 4] Beam Therapeutics Inc. Insider Trading Activity
Beam Therapeutics Inc. CEO John M. Evans reported an automatic sale of 30,078 shares of common stock on April 1, 2026, at $24.58 per share. This non-discretionary transaction was executed to cover tax withholding obligations tied to restricted stock units, as part of a pre-established Rule 10b5-1 trading plan. After the sale, Evans continues to hold a significant number of shares directly and indirectly, demonstrating ongoing equity participation despite the tax-driven disposition.
Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares
Beam Therapeutics insider Christine Bellon recently sold 5,956 shares of the company's stock for over $146,000 to cover tax withholding obligations. This sale is part of a pattern of recent insider selling, including larger disposals in January. Despite these sales, the company reported strong quarterly earnings, significantly beating analyst estimates, and analysts maintain a "Moderate Buy" rating with a consensus target price of $49.36.
John Evans Sells 30,078 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock
Beam Therapeutics CEO John Evans sold 30,078 shares of company stock for over $739,000, primarily to cover tax withholding obligations. This transaction reduced his stake by 2.79%. Despite strong quarterly earnings that significantly beat analyst estimates in revenue and EPS, the company still faces negative net margins and return on equity, with analysts predicting a negative EPS for the current year.
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock
Bethany Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics Inc. (NASDAQ:BEAM), sold 3,242 shares of company stock for a total of $79,688. The sale was executed under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations associated with vested restricted stock units. Despite this insider sale, Beam Therapeutics has recently released positive clinical trial data and received reiterated "Outperform" ratings from several analyst firms.
Why Beam Therapeutics (BEAM) Is Up 12.6% After NEJM Base-Editing Sickle Cell Data Publication
Beam Therapeutics (BEAM) shares rose 12.6% after the publication of positive Phase 1/2 BEACON data for its sickle cell gene therapy, risto-cel, in The New England Journal of Medicine, alongside encouraging results for BEAM-302. These developments support Beam's base-editing platform and reinforce its investment narrative, with risto-cel's potential BLA submission and BEAM-302's planned pivotal cohort acting as key near-term catalysts. Despite the positive news, investors are advised to consider the ongoing conditioning toxicity risk and monitor late-stage safety data.
BEAM SEC Filings - Beam Therapeutics Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Beam Therapeutics Inc. (BEAM) SEC filings, including 10-K, 10-Q, and 8-K forms, as well as insider trading documents. It offers AI-powered summaries to help investors quickly parse key information about the company's financial condition, clinical development, and corporate events. The site also tracks the most recent filings, such as a Q2 2025 earnings report and insider trading activity.
SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM
SG Americas Securities LLC substantially increased its stake in Beam Therapeutics Inc. by 139.4% in Q4, acquiring an additional 60,249 shares to own a total of 103,469 shares valued at approximately $2.87 million. This comes as Beam Therapeutics reported strong quarterly results, significantly beating EPS and revenue expectations with a 280.3% year-over-year revenue increase. The company holds a "Moderate Buy" consensus rating from analysts, with a target price of $49.36.
Assessing Beam Therapeutics (BEAM) Valuation After Major BEACON Trial Milestone For Sickle Cell Therapy
Beam Therapeutics (BEAM) recently announced positive Phase 1/2 BEACON trial results for its sickle cell therapy, risto cel, published in The New England Journal of Medicine. Despite a recent boost in share price, the company has experienced significant volatility long-term. Analysts see a potential fair value of $150 per share, significantly above its current trading price of $24.66, driven by its "Gene Editing 2.0" base editing technology which offers greater precision and safety compared to first-generation gene editors.
CFO of Beam Therapeutics (NASDAQ: BEAM) awarded 31,750 RSUs
Beam Therapeutics' CFO, Sravan Kumar Emany, was granted 31,750 Restricted Stock Units (RSUs) under the company's 2019 Equity Incentive Plan. These RSUs will vest in four equal annual installments, contingent on his continued employment. Following this award, Emany directly holds 105,456 shares of common stock.
Beam Therapeutics (NASDAQ: BEAM) awards 20,000 RSUs to Chief Legal Officer
Beam Therapeutics' Chief Legal Officer, Christine Bellon, was granted 20,000 restricted stock units (RSUs) on March 31, 2026, as reported in a Form 4 SEC filing. These RSUs, which convert to common stock, vest in four equal annual installments contingent on her continued service. After this grant, Bellon directly holds 115,667 shares of Beam common stock, with the award considered compensation-related rather than an open-market purchase.
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells 25,000 Shares of Stock
Beam Therapeutics (NASDAQ:BEAM) CEO John Evans recently sold 25,000 shares of the company's stock for over $559,000, reducing his direct ownership by 2.47%. This sale comes despite the company reporting strong quarterly earnings, significantly beating revenue and EPS estimates, though still showing negative net margins. Analysts maintain a "Moderate Buy" rating with a target price considerably higher than its current trading value.
Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing
An insider at Beam Therapeutics sold shares valued at $1,128,315, as reported in a recent SEC filing. This transaction was disclosed on April 2, 2026. The biotech company is developing precision genetic medicines using base editing technology.
Beam Therapeutics (BEAM) CEO sells 50K shares, gains 90K RSUs
Beam Therapeutics CEO John M. Evans exercised options for 50,000 shares at $0.67 each and subsequently sold all 50,000 shares on the open market at weighted average prices of $22.3692 and $22.7634. These sales were conducted under a Rule 10b5-1 trading plan. Additionally, Evans was granted 90,000 restricted stock units (RSUs) that will vest over four years.
Beam (BEAM) Reports Promising Data from BEACON Trial in Sickle Cell Disease
Beam Therapeutics (BEAM) has released promising results from its Phase 1/2 BEACON clinical trial for ristoglogene autogetemcel (risto-cel), a treatment for sickle cell disease. The data, published in The New England Journal of Medicine, indicates that risto-cel has a favorable safety profile and shows significant efficacy in improving patient outcomes, including rapid bone marrow reconstitution and normalization of key hemolysis markers. Despite financial challenges common to early-stage biotech, the company maintains a strong balance sheet and positive analyst outlook, positioned in the biotechnology sector with a focus on precision genetic medicines.
Beam Therapeutics CEO Evans sells $1.1m in stock
Beam Therapeutics CEO John M. Evans sold 50,000 shares of common stock for approximately $1.1 million on March 30 and 31, 2026, while also acquiring 50,000 shares at a lower price and 90,000 shares at no cost. Following these transactions, Evans directly and indirectly owns over 1.1 million shares. The company has also recently published positive clinical trial data for sickle cell disease and alpha-1 antitrypsin deficiency, leading to reiterated Outperform and Buy ratings from multiple analysts.
In 31 sickle cell patients, Beam saw no severe pain crises after risto-cel
Beam Therapeutics announced the publication of interim Phase 1/2 BEACON data for risto-cel in The New England Journal of Medicine, showing promising results for sickle cell disease treatment. The data from 31 patients demonstrated high fetal hemoglobin levels, reduced sickle hemoglobin, and crucially, no severe vaso-occlusive crises post-engraftment. Beam plans to submit a U.S. Biologics License Application (BLA) for risto-cel as early as year-end 2026, targeting a significant market of eligible SCD patients.
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Beam Therapeutics announced the publication of interim Phase 1/2 BEACON clinical trial data for risto-cel in The New England Journal of Medicine. The investigational autologous cell therapy, designed for severe sickle cell disease, demonstrated an acceptable safety profile and encouraging efficacy, leading to resolution of red blood cell dysfunction and reduced hospital time. The company plans to submit a U.S. Biologics License Application (BLA) for risto-cel as early as year-end 2026, aiming to bring this potential best-in-class treatment to patients.
Why Is BEAM Stock Edging Higher After Hours Today?
Beam Therapeutics (BEAM) shares rose 3% after hours following positive results from a clinical trial for their investigational genetically modified cell therapy, risto-cel, which showed an acceptable safety profile and encouraging efficacy in treating sickle cell disease. The company plans to seek FDA approval for risto-cel as early as year-end 2026. Despite positive trial data, retail sentiment on Stocktwits shifted from 'bullish' to 'neutral.'
ETRADE Financial (NASDAQ: BEAM) insider sales and restricted vesting
A Form 144 filing reveals insider sales and restricted stock vesting for ETRADE Financial (NASDAQ: BEAM). John M. Evans sold a total of 50,000 shares across two transactions in late January 2026, totaling over $1.4 million in gross proceeds. Additionally, 66,874 shares tied to restricted stock vesting for services rendered became effective on March 31, 2026.
[144] Beam Therapeutics Inc. SEC Filing
A Form 144 SEC filing by an affiliate of Beam Therapeutics Inc. (BEAM) indicates a proposed sale of 20,000 shares of common stock, stemming from restricted stock vesting on March 31, 2026. This notice is a regulatory requirement for affiliates planning to resell restricted securities and does not signify an immediate sale. The filing also details prior sales by the same holder in January 2026, totaling over 21,000 shares for more than $725,000.
BEAM (NASDAQ: BEAM) insider schedules 25,000-share sale after option exercise
An insider at Beam Therapeutics Inc. (NASDAQ: BEAM) has scheduled the sale of 25,000 shares after exercising stock options, as indicated by a Rule 144 SEC filing. The filing also notes previous sales by John M. Evans on January 29 and January 30, 2026, each involving 25,000 shares for a total of $734,582.50 and $708,947.50 respectively. This transaction is a routine compliance filing related to the resale of securities following an option exercise.
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data
Beam Therapeutics (BEAM) saw its stock gains fade despite reporting positive early-stage data for its gene-editing therapy, BEAM-302, which showed significant improvement in patients with alpha-1 antitrypsin deficiency (AAT). The therapy demonstrated sustained protective protein levels for up to one year and converted 94% of AAT into its healthy form. Additionally, the company announced plans to advance another liver-targeted gene-editing therapy, BEAM-304, for Phenylketonuria (PKU), with an IND filing expected later in 2026.
JPMorgan Chase & Co. Has $13.14 Million Stock Position in Beam Therapeutics Inc. $BEAM
JPMorgan Chase & Co. has reduced its stake in Beam Therapeutics Inc. by 18% in the third quarter, now holding 541,303 shares valued at $13.14 million. This reduction comes despite Beam Therapeutics reporting a significant earnings beat with $2.33 EPS and $114.11 million in revenue, far exceeding expectations. The stock's performance has been mixed, with shares sliding 6.1% recently, yet analysts maintain a "Moderate Buy" consensus rating with a price target of $49.36.
Beam Therapeutics (BEAM) Is Down 9.9% After Advancing BEAM-302 Into FDA Accelerated Approval Pathway
Beam Therapeutics (BEAM) saw its stock drop 9.9% after announcing it would advance its BEAM-302 therapy for alpha-1 antitrypsin deficiency into pivotal development via an FDA accelerated approval pathway. The company reported positive Phase 1/2 data showing rapid, durable biomarker changes. This move, supported by a new $500 million credit facility, raises the stakes for the company's investment narrative, pivoting towards BEAM-302's potential approval to justify its current valuation and manage ongoing losses.
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Maze Therapeutics, Inc. (MAZE) and Daiichi Sankyo Company (OtherDSKYF)
This article highlights bullish sentiments from financial analysts towards three healthcare companies: Beam Therapeutics (BEAM), Maze Therapeutics, Inc. (MAZE), and Daiichi Sankyo Company (DSKYF). J.P. Morgan analysts maintained Buy ratings for all three, with specific price targets and potential upsides noted. The consensus from the street for all three companies is a Strong Buy.
Beam Therapeutics (NASDAQ:BEAM) Price Targets Rise As Nasdaq Futures Move
This article discusses Beam Therapeutics (NASDAQ:BEAM) stock movement, highlighting its valuation changes, strong institutional involvement, and position in the biotech sector, especially in light of current Nasdaq futures trends. The content emphasizes the company's focus on genetic medicine innovation. To read the full article, readers are prompted to log in or register.
Vanguard disaggregates holdings; reports 0% in Beam Therapeutics (NASDAQ: BEAM)
The Vanguard Group filed an amended Schedule 13G/A reporting 0% beneficial ownership of Beam Therapeutics (BEAM) common stock. This update follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries began reporting holdings separately. As a result, The Vanguard Group itself now reports holding 0 shares and 0% ownership in Beam Therapeutics.
Beam To Extend Current Trial For Pivotal BEAM-302 Development
Beam Therapeutics announced updated data from its Phase I/II trial for BEAM-302 and revealed its plans for pivotal development. The company is set to extend its current trial as it moves forward with the advancement of BEAM-302.
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
Beam Therapeutics (BEAM) reported strong updated safety and efficacy data from its phase I/II study of BEAM-302 for alpha-1 antitrypsin deficiency (AATD). The data, showcasing a favorable tolerability profile and significant reductions in mutant Z-AAT levels, supports BEAM-302 as a potential first-in-class, one-time treatment. The company plans global expansion of the study for accelerated approval, with 60 mg identified as the optimal dose.
Beam Therapeutics stock holds at Outperform on AATD data
Bernstein SocGen Group reiterated an Outperform rating and $40 price target for Beam Therapeutics (NASDAQ:BEAM) after new clinical data for alpha-1 antitrypsin deficiency (AATD) showed improved serum AAT levels. The company identified 60 mg as the pivotal dose for future development, with results exceeding analyst expectations. This positive data, along with the company's strong cash position, suggests significant upside potential despite some investor skepticism regarding methodology changes.
Beam Therapeutics stock holds at Outperform on AATD data
Bernstein SocGen Group has reiterated an Outperform rating and a $40 price target for Beam Therapeutics (NASDAQ:BEAM) after the company released new clinical data for its alpha-1 antitrypsin deficiency (AATD) treatment, BEAM-302, which surpassed expectations. Other analysts like Leerink Partners, William Blair, and Clear Street also maintained positive ratings, with Leerink raising its price target to $47. The stock is currently trading at $23.12, suggesting significant potential upside according to Wall Street analysts.
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics announced updated, compelling clinical data from its Phase 1/2 trial of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD), highlighting the 60 mg dose as optimal for pivotal development. The treatment showed significant and durable increases in functional AAT, reductions in toxic Z-AAT, and M-AAT composition, with a well-tolerated safety profile. The company plans to pursue an accelerated approval pathway with the FDA and expects to initiate a pivotal cohort in the second half of 2026.
Beam Therapeutics shares climb after positive BEAM-302 trial update
NULL
A Look At Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated Approval Plans
Beam Therapeutics (BEAM) shares are under scrutiny following positive Phase 1/2 data for its AATD candidate BEAM-302 and plans for accelerated approval. Despite a narrative valuation of $150 suggesting the stock is 84% undervalued, its current P/S ratio of 17x significantly exceeds industry averages, indicating potential valuation risk. The market is weighing the promising clinical catalysts against the company's current unprofitability and recent stock performance, which shows short-term losses but a positive one-year return.
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels
Beam Therapeutics (NASDAQ: BEAM) shares rose after announcing positive updated safety and efficacy data from its Phase 1/2 trial for BEAM-302, a gene therapy for alpha-1 antitrypsin deficiency (AATD). The trial showed that BEAM-302 achieved and maintained protective protein levels above the 11 µM threshold with a favorable safety profile. The company plans to pursue accelerated approval based on AAT biomarkers and initiate a pivotal cohort in the second half of 2026.
Leerink raises Beam Therapeutics stock price target on AATD data
Leerink Partners increased its price target for Beam Therapeutics (NASDAQ:BEAM) to $47 from $42, maintaining an Outperform rating, following updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency (AATD). The 60 mg dose of BEAM-302 showed promising results in AAT levels and reduction of mutant Z-AAT, leading to the selection of this dose for further development. This optimism is shared by other analysts, with a consensus target of $45.50 suggesting significant upside, and the company plans to enroll additional patients for an accelerated approval study in the latter half of 2026.
BEAM: BEAM-302 at 60 mg delivers durable, functional AAT restoration and strong safety in AATD
Beam Therapeutics (BEAM) has released updated Phase 1/2 data for BEAM-302, showing that a 60 mg dose significantly increases functional AAT and reduces mutant Z-AAT in patients with Alpha-1 Antitrypsin Deficiency (AATD) with a strong safety profile. The company plans to use the 60 mg dose for pivotal development and target accelerated approval. This summary is AI-generated and should be verified with the original source.
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics announced updated compelling clinical data from its Phase 1/2 trial of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD), showing significant increases in functional AAT, reductions in mutant Z-AAT, and a well-tolerated safety profile. The company has selected a 60 mg dose for pivotal development and plans to pursue an accelerated approval pathway for this one-time genetic medicine. A global pivotal cohort is expected to initiate in the second half of 2026, building on strong evidence of correcting the underlying genetic mutation in patients.
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Beam Therapeutics announced positive updated Phase 1/2 clinical data for BEAM-302 in patients with Alpha-1 Antitrypsin Deficiency (AATD). A 60 mg dose of BEAM-302 led to significant and durable increases in protective AAT levels, reductions in toxic Z-AAT, and M-AAT composition, with a well-tolerated safety profile. The company plans to advance the 60 mg dose into pivotal development in the second half of 2026 to support potential accelerated approval.
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Moderate Buy" from Analysts
Beam Therapeutics Inc. (NASDAQ:BEAM) has received a consensus "Moderate Buy" rating from sixteen analysts, with an average 12-month price target of $47.50. Despite a significant quarterly earnings beat, the company remains unprofitable. Institutional investors hold a large stake, and there has been recent insider selling from Christine Bellon.
Beam Therapeutics Inc. (BEAM) reports Q4 loss, beats revenue estimates
Beam Therapeutics Inc. (BEAM) reported a narrower-than-expected loss for the fourth quarter, coming in at $1.20 per share compared to the Zacks Consensus Estimate of a $1.29 loss. Despite the beat on earnings, the reported loss was wider than the $0.87 per share loss in the prior-year quarter. The company surpassed revenue expectations, posting $26.11 million against an estimated $21.57 million, and projects its cash and equivalents to fund operations into the second half of 2026.
Beam Therapeutics Inc. (BEAM) reports Q4 loss, beats revenue estimates
Beam Therapeutics Inc. (BEAM) reported a narrower-than-expected loss of $0.98 per share for the fourth quarter, surpassing the Zacks Consensus Estimate of a $1.09 loss. The company also beat revenue estimates, reporting $20.8 million against an expected $17.1 million. Despite beating estimates, the quarterly revenue declined by 10.3% year-over-year.
(BEAM) Movement as an Input in Quant Signal Sets
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It identifies an exceptional 59.6:1 risk-reward setup, targeting a 16.8% gain with minimal risk, and presents institutional trading strategies for various risk profiles. The analysis includes AI-generated signals and multi-timeframe support/resistance levels.
Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)
Three healthcare stocks, Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS), and Vertex Pharmaceuticals (VRTX), have received bullish sentiments from analysts. Analysts Alec Stranahan (Beam Therapeutics), James Molloy (Pelthos Therapeutics), and Tazeen Ahmad (Vertex Pharmaceuticals) maintained or reiterated Buy ratings, citing significant upside potential for these companies. The Street generally suggests a Strong Buy consensus for all three, with impressive average price targets and projected returns.
Beam Therapeutics (Nasdaq:BEAM) - Stock Analysis
This stock analysis provides an overview of Beam Therapeutics (BEAM), highlighting its current market cap, share price, and financial health. The company is involved in developing precision genetic medicines, with revenue forecast to grow significantly despite expected earnings decline and current unprofitability. The report also includes analyst narratives on the company's base editing technology, its potential for treating genetic diseases, and recent news and updates.
Farallon Capital Management LLC Purchases 50,000 Shares of Beam Therapeutics Inc. $BEAM
Farallon Capital Management LLC increased its stake in Beam Therapeutics Inc. by 0.5% during the third quarter, acquiring an additional 50,000 shares. This makes Beam Therapeutics its 29th largest position, accounting for 1.0% of its investment portfolio. Other institutional investors like Jones Financial Companies Lllp and UBS AM also significantly modified their holdings in BEAM, while analysts have given the stock a "Moderate Buy" consensus rating with a target price of $47.50.
